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Prothrombin complex concentrates (PCCs) are recom-mended internationally for emergency reversal of vita-min K antagonists, with recent data indicating superior 
efficacy versus therapeutic plasma.1 The use of PCCs for rever-
sal of direct oral anticoagulants has also been investigated.
In Europe, PCCs may be used to treat excessive bleeding 
that is unrelated to anticoagulant therapy, where the patho-
physiology of bleeding is entirely different from patients 
requiring reversal of anticoagulant therapy. Patients taking oral 
anticoagulant therapy have reductions in a limited number of 
specific proteins.2 In contrast, trauma/perioperative bleed-
ing patients have generalized reductions of all procoagulants 
and anticoagulants. Administration of procoagulant therapy 
without cosupplementation of anticoagulants may therefore 
introduce an imbalance in the coagulation system, increasing 
the risk of thromboembolic complications.3,4 Monitoring and, 
if necessary, supplementing plasma levels of antithrombin 
(AT) has been suggested as 1 approach to improving the safety 
of PCCs.3,4 Administration of PCC for perioperative bleeding 
may be guided by clotting time in the thromboelastometric 
EXTEM assay or the international normalized ratio. However, 
neither of these measures is sensitive to AT levels.
Our group previously developed a mathematical model 
to show theoretical relationships between amounts of ther-
apeutic plasma/cryoprecipitate/fibrinogen concentrate 
and plasma fibrinogen level.5 Using a similar approach, 
we designed a theoretical, educational tool to answer the 
question “What would be the resultant factor II (FII) level, 
AT level, and FII:AT ratio when administering a specified 
amount of therapeutic plasma or PCC?”
METHODS
A mathematical model was constructed to examine rela-
tionships between the amount of hemostatic agent (PCC or 
therapeutic plasma) and plasma levels of FII and AT. Details 
of the assumptions for developing the model are shown in 
Supplemental Digital Content 1 (http://links.lww.com/
AA/B954). Briefly, they were as follows:
 1. The patient starts with a certain plasma volume, FII 
level, and AT level.
 2. Hemostatic agent is added 1 unit at a time.
 3. Volume resuscitation with crystalloid or colloid may 
be coadministered.
 4. Immediately before adding each unit of hemostatic 
agent, the volume of the unit plus the volume of 
crystalloid or colloid is removed from circulation.
 5. On adding each unit of hemostatic agent plus crys-
talloid or colloid, plasma volume is restored to the 
“baseline” volume.
 6. After adding each unit of hemostatic agent, new values 
for FII level, AT level, and FII:AT ratio are calculated.
 7. If hematocrit decreases below a defined threshold, 1 
unit red blood cells (RBC) is added to the simulation 
at the same time as the next unit of hemostatic agent.
Prothrombin complex concentrates (PCCs) have been associated with a possible risk of throm-
boembolic complications, potentially attributable to an increased ratio of the plasma concentra-
tion of factor II (FII) to antithrombin (AT). We developed a mathematical model to examine the 
relationship between amounts of PCC or therapeutic plasma administered, and plasma levels 
of FII and AT. The model showed that PCC produces substantial increases in plasma levels of 
FII but only small changes in AT, increasing the FII:AT ratio. Therapeutic plasma was shown to 
have only modest effects on levels of FII or AT, unless high doses are used.  (Anesth Analg 
2017;125:1471–4)
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Using literature-based values for key parameters, the model 
was initially developed with mathematical consideration of 
blood plasma and the constituents of interest (please see 
Supplemental Digital Content 1, http://links.lww.com/
AA/B954).
Several refinements were then incorporated, using simi-
lar methodology to that described for the fibrinogen concen-
tration simulator (Supplemental Digital Content 1, http://
links.lww.com/AA/B954).5 In vivo recovery was added 
and the model was modified to keep circulatory volume 
constant. The addition of RBC when hematocrit falls below 
a defined threshold was also added to the model.
RESULTS
Initial results from the finalized tool, with bodyweight 70 kg, 
baseline hematocrit 40%, FII 100%, and AT 100% are shown 
in the Figure. PCC (2000 IU) elicited considerable increase 
in the plasma level of FII but little change in AT. Therapeutic 
plasma (4 U) had little impact on levels of either FII or AT. 
Thus, PCC increased the FII:AT ratio to 1.89, whereas this 
ratio remained at 1.00 with therapeutic plasma. When base-
line levels of FII and AT were reduced to 40%, PCC still 
increased the FII level above normal (130%) while plasma 
increased it only to 56%. AT changed little in response to 
PCC, and increased to 56% with therapeutic plasma. The 
FII:AT ratio remained at 1.00 with therapeutic plasma but 
increased with PCC to 3.15.
A new set of baseline parameters was then used: body-
weight 120 kg, hematocrit 50%, FII 40%, and AT 60%. Six 
units of therapeutic plasma and 3000 IU of PCC were mod-
eled (12.5 mL/kg and 25 IU/kg, respectively). Volume resus-
citation was also included: 150 mL per unit of PCC (zero with 
therapeutic plasma). The simulator showed that PCC pro-
duced almost a 3-fold increase in FII, to 115%, and there was 
a decrease in AT to 50%. Thus, the FII:AT ratio was increased 
to 2.31 (Supplemental Digital Content 2, http://links.lww.
com/AA/B955). With therapeutic plasma, modest increases 
in FII and AT were observed (resultant levels of 56% and 
71%), so the FII:AT ratio was increased from 0.67 to 0.80.
The original scenario was then reassessed, with a low 
baseline hematocrit (22%). This resulted in a unit of RBC 
being added along with the second unit of therapeutic 
plasma, reducing the levels of FII and AT in circulation with-
out affecting the FII:AT ratio (Supplemental Digital Content 
2, http://links.lww.com/AA/B955). The unit of RBC was 
successful in increasing hematocrit above the 21% threshold.
The tool was applied to simulate situations described in 
cardiovascular surgery, trauma and vitamin K antagonist 
reversal (Supplemental Digital Content 2, http://links.lww.
com/AA/B955).
DISCUSSION
This theoretical tool indicates that, under most conditions, 
addition of PCC increases the FII:AT ratio. In contrast, 
therapeutic plasma has only modest effects on levels of 
FII or AT, with little effect on the FII:AT ratio. Due to dilu-
tional effects, plasma levels of FII and AT do not necessar-
ily increase linearly with increasing dose of therapeutic 
plasma. In comparison, infusion volumes of PCC are rela-
tively small, meaning that increases in plasma levels of FII 
and AT are generally linear. Our results also indicate that 
a small amount of PCC can be far more effective than a 
moderate or large dose of therapeutic plasma in increasing 
thrombin generation potential. This can be explained by the 
relatively low concentrations of coagulation factors in thera-
peutic plasma.
The pathophysiology of bleeding differs greatly between 
clinical settings. For emergency reversal of anticoagula-
tion relating to vitamin K antagonist therapy, the risk of 
thromboembolic complications caused by PCC appears 
low.6 This may be related to normal levels of AT2; conse-
quently, patients may have an FII:AT ratio close to 1 after 
treatment with PCC (see Supplemental Digital Content 2, 
http://links.lww.com/AA/B955). However, in trauma and 
perioperative bleeding, generalized depletion of both pro- 
and anticoagulants is common, and PCC therapy is likely 
to increase the FII:AT ratio above 1. Therefore, a cautious 
approach when administering PCC appears warranted in 
trauma and perioperative bleeding. It has been suggested 
that adequate levels of fibrinogen should be ensured before 
PCC therapy in such settings.7 A treatment strategy with 
combined use of fibrinogen supplementation and PCC with 
AT has been supported by data obtained from kinetic mod-
eling of thrombin generation.8 Our tool does not include 
AT concentrate. However, the effects of using PCC plus AT 
could be modeled by increasing the quantity of AT and the 
volume per unit of PCC.
Limitations of the tool we designed include a lack of 
accounting for clinical realities such as ongoing bleeding, 
loss/consumption of coagulation factors, administration 
of additional therapies such as platelets, or the timing of 
events such as administration of PCC or therapeutic plasma. 
Therefore, clinical validation of the tool in patients with peri-
operative bleeding is not possible. The clinical risk of throm-
boembolism is affected by many factors apart from the FII:AT 
ratio, and the clinical implications of a change in the FII:AT 
ratio are poorly defined. Therefore, the extent to which our 
tool reflects patients’ risk of thromboembolism is uncertain.
Despite the limitations, there is good evidence that 
FII:AT ratio may affect the risk of thromboembolic events. 
First, an in vitro study implicated FII as the primary cause of 
thrombogenic potential with PCCs, and suggested that the 
ratio between FII and AT must be restored to reduce throm-
bin generation to normal levels.3 Second, a porcine trauma 
model showed that PCC (35 IU/kg) was well tolerated and 
effective in improving coagulation.7 However, 50 IU/kg 
PCC was associated with thromboembolism and signs of 
disseminated intravascular coagulation. Supplementation 
of factors II, IX, and X after hemodilution has been shown in 
computational modeling to increase thrombin generation, 
but with coadministration of AT thrombin generation was 
restored to baseline (predilution) levels.9 Finally, a study 
using blood samples from cardiac surgery patients supports 
the likelihood of excessive thrombin generation capacity 
after PCC therapy without AT supplementation.10
In conclusion, PCC may be a valuable treatment for 
increasing thrombin generation capacity in patients with 
coagulopathy and life-threatening bleeding. We devel-
oped a theoretical tool to examine the effects of PCC on 
the patient’s FII:AT ratio, and the results highlight impor-
tant differences between patients requiring reversal of oral 
Modeling Coagulation Management—Plasma or PCC
November 2017 • Volume 125 • Number 5 www.anesthesia-analgesia.org 1473
anticoagulant therapy and those with trauma/periopera-
tive bleeding. Caution may be required with regard to the 
potential for PCC to produce a prothrombotic imbalance, 
particularly in patients with bleeding unrelated to antico-
agulant therapy. A strategy of supplementing AT among 
recipients of PCC could be considered. E
DISCLOSURES
Name: Herbert Schöchl, MD.
Contribution: This author helped conceptualize the project, 
develop the mathematical formulae and coding for the electronic 
tool, advice regarding trauma, contributed to the assumptions 
on which the modeling was based, and reviewed it critically and 
approved the final version.
Figure. Results obtained with the finalized, theoretical FII-AT concentration simulator. Seventy-kilogram patient with 40% hematocrit, baseline 
plasma levels of FII and AT of 100%, and addition of 4 units of PCC and therapeutic plasma. AT indicates antithrombin; FII, factor II; PCC, 
prothrombin complex concentrate.
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